Kozak & Associates Inc. Has $130,000 Stock Position in Abbott Laboratories (NYSE:ABT)

Kozak & Associates Inc. lowered its stake in Abbott Laboratories (NYSE:ABT) by 8.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,146 shares of the healthcare product maker’s stock after selling 102 shares during the quarter. Kozak & Associates Inc.’s holdings in Abbott Laboratories were worth $130,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the stock. Lantz Financial LLC boosted its position in shares of Abbott Laboratories by 5.2% during the 2nd quarter. Lantz Financial LLC now owns 5,737 shares of the healthcare product maker’s stock worth $596,000 after acquiring an additional 281 shares in the last quarter. Umpqua Bank increased its holdings in Abbott Laboratories by 4.0% in the second quarter. Umpqua Bank now owns 5,482 shares of the healthcare product maker’s stock worth $570,000 after purchasing an additional 211 shares in the last quarter. Strategic Financial Concepts LLC acquired a new stake in Abbott Laboratories in the second quarter valued at approximately $116,000. Chris Bulman Inc acquired a new position in Abbott Laboratories during the second quarter worth $142,000. Finally, Acadian Asset Management LLC boosted its stake in Abbott Laboratories by 510.6% during the 2nd quarter. Acadian Asset Management LLC now owns 319,169 shares of the healthcare product maker’s stock valued at $33,156,000 after purchasing an additional 266,899 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ABT has been the topic of several research reports. Piper Sandler lifted their price objective on shares of Abbott Laboratories from $131.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, October 17th. Royal Bank of Canada raised their price target on shares of Abbott Laboratories from $125.00 to $130.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Jefferies Financial Group increased their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research report on Thursday, October 17th. Mizuho raised their target price on shares of Abbott Laboratories from $115.00 to $130.00 and gave the company a “neutral” rating in a research note on Thursday, October 17th. Finally, Morgan Stanley upped their target price on Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $131.57.

Abbott Laboratories Price Performance

ABT traded down $0.03 during midday trading on Monday, hitting $113.80. 1,988,560 shares of the company traded hands, compared to its average volume of 3,288,691. The business has a 50 day simple moving average of $115.47 and a two-hundred day simple moving average of $112.27. Abbott Laboratories has a 52-week low of $99.71 and a 52-week high of $121.64. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $197.38 billion, a price-to-earnings ratio of 34.59, a PEG ratio of 2.69 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, topping the consensus estimate of $1.20 by $0.01. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.14 EPS. On average, equities analysts forecast that Abbott Laboratories will post 4.67 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 dividend on an annualized basis and a yield of 2.07%. Abbott Laboratories’s payout ratio is currently 71.73%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.